journals.asm.org
Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections | Antimicrobial Agents and Chemotherapy
Musculoskeletal infections in children, including acute hematogenous osteomyelitis and septic arthritis, are among the most common severe infections affecting children. Staphylococcus aureus is the most common bacterial etiology, with most isolates remaining methicillin-susceptible S. aureus (MSSA) throughout the United States (1). The current standard of care for treating pediatric musculoskeletal infections includes a short course of intravenous (IV) therapy, followed by prolonged oral treatment, to complete 3–6 total weeks (1–5).